GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advanced Proteome Therapeutics Corp (OTCPK:APTCF) » Definitions » Return-on-Tangible-Asset

Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Return-on-Tangible-Asset : -3,039.59% (As of Apr. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Advanced Proteome Therapeutics Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Advanced Proteome Therapeutics's annualized Net Income for the quarter that ended in Apr. 2023 was $-5.91 Mil. Advanced Proteome Therapeutics's average total tangible assets for the quarter that ended in Apr. 2023 was $0.19 Mil. Therefore, Advanced Proteome Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Apr. 2023 was -3,039.59%.

The historical rank and industry rank for Advanced Proteome Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:

APTCF's Return-on-Tangible-Asset is not ranked *
in the Biotechnology industry.
Industry Median: -40.01
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

Advanced Proteome Therapeutics Return-on-Tangible-Asset Historical Data

The historical data trend for Advanced Proteome Therapeutics's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Proteome Therapeutics Return-on-Tangible-Asset Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -409.34 -189.74 -482.35 -399.78 99.09

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -219.08 -40.78 -162.32 -306.76 -3,039.59

Competitive Comparison of Advanced Proteome Therapeutics's Return-on-Tangible-Asset

For the Biotechnology subindustry, Advanced Proteome Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Proteome Therapeutics's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advanced Proteome Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Advanced Proteome Therapeutics's Return-on-Tangible-Asset falls into.



Advanced Proteome Therapeutics Return-on-Tangible-Asset Calculation

Advanced Proteome Therapeutics's annualized Return-on-Tangible-Asset for the fiscal year that ended in Jul. 2022 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Jul. 2022 )  (A: Jul. 2021 )(A: Jul. 2022 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Jul. 2022 )  (A: Jul. 2021 )(A: Jul. 2022 )
=0.76/( (0.898+0.636)/ 2 )
=0.76/0.767
=99.09 %

Advanced Proteome Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Apr. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Apr. 2023 )  (Q: Jan. 2023 )(Q: Apr. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Apr. 2023 )  (Q: Jan. 2023 )(Q: Apr. 2023 )
=-5.912/( (0.326+0.063)/ 2 )
=-5.912/0.1945
=-3,039.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Apr. 2023) net income data.


Advanced Proteome Therapeutics  (OTCPK:APTCF) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Advanced Proteome Therapeutics Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Advanced Proteome Therapeutics's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Business Description

Traded in Other Exchanges
Address
8337 Eastlake Drive, Suite 104, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.

Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Headlines